Clinical Trials on Metastatic gpNMB Over-expressing Triple Negative Breast Cancer

Total 1007 results

Rush University Medical Center

Completed

Patterns of Prescribing and Monitoring of Palbociclib

Advanced Breast Cancer | Metastatic Breast Cancer | Estrogen Receptor-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Regeneron Pharmaceuticals

Suspended

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Merkel Cell Carcinoma | Basal Cell Carcinoma | Oropharynx Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States, Australia
Helwan University

Not yet recruiting

Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients. (Palbociclib)

Metastatic Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Hormone-receptor-positive Breast Cancer
Novartis Pharmaceuticals

Completed

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

United States, Spain, Taiwan, Germany, Netherlands, United Kingdom, Korea, Republic of
Fusion Pharmaceuticals Inc.

Recruiting

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection

Cervical Cancer | Breast Cancer | Ovarian Cancer | Endometrial Cancer | Uveal Melanoma | Adrenocortical Carcinoma | Advanced Solid Tumours | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Head and Neck Squamous Cell Carcinoma (HNSCC)

United States, Australia, Canada
Marina N Sharifi
Novartis; University of Wisconsin, Madison

Recruiting

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | PIK3CA Mutant Metastatic Breast Cancer

United States
Rubius Therapeutics

Terminated

RTX-224 Monotherapy in Patients With Solid Tumors

Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Cutaneous Melanoma | TNBC - Triple-Negative Breast Cancer

United States
Novartis Pharmaceuticals

Terminated

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Melanoma | Head and Neck Cancer | Pancreatic Cancer | Urothelial Cancer | NSCLC, Non Small Cell Lung Cancer | RCC, Renal Cell Cancer | DLBCL, Diffused Large B Cell Lymphoma | MSS, Microsatellite Stable Colon Cancer | TNBC, Triple Negative Breast Cancer | mCRPC, Metastatic Castration Resistant Prostate...

Belgium, Italy, Taiwan, Germany, Spain, United States, Argentina, Australia, Austria, Czechia, France, Japan, Netherlands, Switzerland, Singapore
Barretos Cancer Hospital

Completed

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

BRCA1 Hereditary Breast and Ovarian Cancer Syndrome

Brazil
Infinity Pharmaceuticals, Inc.
Roche Pharma AG

Active, not recruiting

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)

Renal Cell Carcinoma | Breast Cancer

United States
Simcha IL-18, Inc.
Merck Sharp & Dohme LLC

Recruiting

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Melanoma | Carcinoma | Renal Cell Carcinoma | Cancer | Solid Tumor | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Triple-negative Breast Cancer | MSI-High

United States
National Cancer Institute (NCI)

Withdrawn

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Negative Breast Carcinoma | Unresectable HER2-Negative Breast Carcinoma
Genentech, Inc.

Recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Korea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

China
Calithera Biosciences, Inc

Terminated

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Clear Cell Renal Cell Carcinoma | Colorectal Cancer | Solid Tumor | CRC | TNBC - Triple-Negative Breast Cancer | ccRCC | RCC

United States
Institut Bergonié
Boehringer Ingelheim

Not yet recruiting

Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures (EMPIRE)

Colorectal Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Biliary Tract Cancer | Adult Soft Tissue Sarcoma

France
CytoMed Therapeutics Pte Ltd

Unknown

Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour

Sarcoma | Nasopharyngeal Carcinoma | Gastric Cancer | Colorectal Cancer | Prostate Cancer | Triple Negative Breast Cancer

Malaysia
Silverback Therapeutics

Withdrawn

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Urothelial Carcinoma | Hormone Receptor-positive/HER2-negative Breast Cancer
ProfoundBio US Co.

Recruiting

PRO1107 in Patients With Advanced Solid Tumors

Ovarian Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Urothelial Carcinoma | GastroEsophageal Cancer

United States
Relay Therapeutics, Inc.

Active, not recruiting

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Unresectable Solid Tumor | PIK3CA Mutation

United States
MedImmune LLC

Completed

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer

Spain, United States, Belgium, France, United Kingdom, Canada, Israel, Germany, Hungary, Poland, Bahamas
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
Eli Lilly and Company

Terminated

A Study of LY3435151 in Participants With Solid Tumors

Hepatocellular Carcinoma | Solid Tumor | Gastric Adenocarcinoma | Leiomyosarcoma | Head and Neck Squamous Cell Carcinoma | Cervical Carcinoma | Triple-negative Breast Cancer | Undifferentiated Pleomorphic Sarcoma | High Grade Serous Ovarian Carcinoma

United States, Japan
Eli Lilly and Company

Terminated

A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors

Renal Cell Carcinoma | Solid Tumor | Non Small Cell Lung Cancer | Triple Negative Breast Cancer

Belgium, Spain, United States, France, Italy, Denmark
TransThera Sciences (Nanjing), Inc.

Recruiting

To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Gastric Cancer | Prostate Cancer | Cholangiocarcinoma | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Small-cell Lung Cancer | Thyroid Cancer | Biliary Tract Cancer | Gallbladder Cancer | HER2-negative Breast Cancer

China
Assistance Publique - Hôpitaux de Paris

Unknown

A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer (PALPETBIO)

Breast Cancer | Metastasis | HR+/HER2-negative Breast Cancer
Novartis Pharmaceuticals

Completed

Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients (MACS1295)

First or Second Line HER2-negative Breast Cancer | Metastatic Disease Without Bone Metastasis

United States
NeoImmuneTech
Merck Sharp & Dohme LLC

Active, not recruiting

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (KEYNOTE A60)

Small Cell Lung Cancer | Pancreatic Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Microsatellite Stable Colorectal Cancer | Any Advanced Solid Tumors

United States
Puma Biotechnology, Inc.

Not yet recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)

Metastatic Breast Cancer | Recurrent Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer

United States
University of Kansas Medical Center

Recruiting

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry (PROGECT)

Breast Cancer | Hereditary Breast and Ovarian Cancer

United States
NeoTX Therapeutics Ltd.
AstraZeneca

Active, not recruiting

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Ovarian Cancer | NSCLC | Prostate Cancer | Mesothelioma | Bladder Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Colorectal Cancer Metastatic | Head and Neck Squamous Cell Carcinoma | Urothelial Cancer | Cervical Squamous... and other conditions

Israel
Nuvation Bio Inc.

Recruiting

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Breast Carcinoma | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumor | Cancer of the Ovary | Pancreas Cancer | Triple-negative Breast Cancer | Cancer of Pancreas | Pancreas Neoplasm | Prostate Neoplasm | Cancer... and other conditions

United States, Australia
Ikena Oncology
Gilead Sciences

Terminated

A Study of PY314 in Subjects With Advanced Solid Tumors

Renal Cell Carcinoma | Breast Cancer | Gynecologic Cancer | Colorectal Cancer | Ovarian Cancer | Lung Adenocarcinoma | Triple Negative Breast Cancer | Advanced Solid Tumor | Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer

United States
National Cancer Institute (NCI)
AstraZeneca

Active, not recruiting

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Metastatic Lung Non-Small Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Advanced Malignant Solid Neoplasm | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IIIA Lung Non-Small... and other conditions

United States, Canada
Mundipharma Research Limited

Completed

Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors

Soft Tissue Sarcoma | Ovarian Cancer | Endometrial Cancer | Small-cell Lung Cancer | Triple-negative Breast Cancer

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7

United States
University Hospital, Tours
Institut Cancerologie de l'Ouest

Terminated

A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer (DHALYA)

Metastatic Breast Cancer | Estrogen Receptor Positive Tumor | Progesterone Receptor Positive Tumor | HER-2 Negative Tumor

France
BeiGene

Completed

Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

Triple Negative Breast Cancer | Advanced High-grade Ovarian Cancer

China
Kymab Limited
Sanofi

Active, not recruiting

Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Metastatic Cancer | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Cancer

United States, Hungary, Italy, Poland, Taiwan, United Kingdom
TransThera Sciences (Nanjing), Inc.

Completed

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Sarcoma | Gastric Cancer | Prostate Cancer | Cholangiocarcinoma | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Small-cell Lung Cancer | Thyroid Cancer | Gallbladder Cancer | HER2-negative Breast Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Not yet recruiting

Access to Genetic Testing in Underserved Patients With Cancer

Malignant Solid Neoplasm | Breast Carcinoma | Metastatic Prostate Carcinoma | Ovarian Carcinoma | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Pancreatic Exocrine Neoplasm | Stage IVB Prostate Cancer American Joint Committee on Cancer v8

United States
Mersana Therapeutics

Recruiting

A Study of XMT-1660 in Participants With Solid Tumors

Breast Cancer | Adenoid Cystic Carcinoma | Ovarian Cancer | Fallopian Tube Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Primary Peritoneal Cavity Cancer

United States
MacroGenics

Completed

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Cervical Cancer | Hematologic Neoplasms | Ovarian Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Small-cell Lung Cancer | TNBC - Triple-Negative Breast Cancer | HER2-positive Advanced Solid Tumors

Hong Kong, United States, Thailand, Australia, Spain, Bulgaria, Poland, Ukraine
AbbVie

Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Hepatocellular Carcinoma | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancers | Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Head and Neck Squamous-Cell Carcinoma

United States, Israel, Japan, Puerto Rico, Korea, Republic of, Taiwan
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Melanoma | Lymphoma | Head and Neck Cancer | Gastric Cancer | Ovarian Cancer | Hepatocellular Carcinoma (HCC) | Lung Cancer | Bladder Cancer | Endometrial Cancer | Solid Tumors | Renal Cell Carcinoma (RCC) | Triple Negative Breast Cancer (TNBC) | UC (Urothelial Cancer) | Microsatellite-instability (MSI) High Colorectal...

United States
Emory University
National Cancer Institute (NCI); Pfizer; National Institutes of Health (NIH)

Completed

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (ASPIRE)

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Metastatic Breast Carcinoma

United States
Eisai Inc.

Completed

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Locally Recurrent | Metastatic Breast Cancer ( HER2 Negative)

United States
German Breast Group
GlaxoSmithKline; Stemline Therapeutics, Inc.

Not yet recruiting

Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer (ELEMENT)

BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast Cancer

Germany
H. Lee Moffitt Cancer Center and Research Institute
Precigen, Inc

Recruiting

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Triple Negative Breast Cancer Malignancies

United States
VastBiome

Recruiting

The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors (PARADIGM)

Renal Cell Carcinoma | Non-Small-Cell Lung Carcinoma | Malignant Melanoma | Triple-Negative Breast Cancer

United States

Clinical Trials on Metastatic gpNMB Over-expressing Triple Negative Breast Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations